A study published in the American Journal of Epidemiology has associated omega-3 intake with an increased risk of prostate cancer-results that even surprised the researchers, who urged that their findings not be taken too seriously yet.
A study published in the American Journal ofEpidemiology has associated omega-3 intake with an increased risk of prostate cancer-results that even surprised the researchers, who urged that their findings not be taken too seriously yet.
Researchers at Seattle’s Fred Hutchinson Cancer Research Center sought to identify any associations between prostate cancer and dietary intake of omega-3s, omega-6s, or trans fatty acids. Blood levels of each nutrient were taken from over 3000 subjects (55 to 84 years old) who participated in a 1994–2003 Prostate Cancer Prevention Trial. Participants were evaluated for prostate cancer for seven years.
“Specifically, we thought that omega-3 fatty acids would reduce and omega-6 and trans fatty acids would increase prostate cancer risk,” said lead researcher Theodore Brasky, PhD.
In fact, the results were quite the opposite. Subjects in the highest quartile of omega-3 docosahexaenoic acid (DHA) consumption were 2.5 times more likely to be diagnosed with high-grade prostate cancers than subjects with the lowest consumption. Furthermore, trans fatty acids were linearly and inversely associated with high-grade prostate cancer risk. A risk reduction of as much as 50% was observed in subjects with the highest consumption rates.
So why didn’t omega-3s-known for their anti-inflammatory properties-provide a risk reduction? The researchers proposed that omega-3s might affect biological processes related to prostate cancer beyond inflammation. They insisted that more research is warranted on this area of study.
“Overall, the beneficial effects of eating fish to prevent heart disease outweigh any harm related to prostate cancer risk,” Brasky said. “What this study shows is the complexity of nutrition and its impact on disease risk, and that we should study such associations rigorously rather than make assumptions.”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.